Abstract
Type 2 diabetes mellitus (T2DM) is a highly prevalent and progressive metabolic disease associated with significant morbidity and mortality. While glycemic control remains the cornerstone of disease treatment, successful T2DM management requires consideration of several comorbid risk factors including overweight/obesity, dyslipidemia, and hypertension. Early and aggressive treatment of patients with T2DM should be implemented to slow disease progression and prevent long-term complications. This necessitates the selection of antidiabetes agents that effectively lower hyperglycemia and target the other fundamental defects of T2DM. Treatment regimens should be individualized according to patient profiles and risk factors. This is especially germane for overweight/obese patients with T2DM, who have an even higher risk for complications. Several newer antidiabetes agents, in particular, incretin-based therapies, target the underlying defects of T2DM, provide glycemic control with beneficial effects on cardiovascular risk factors including lipids and blood pressure while avoiding weight gain. These represent important therapeutic options for the management of patients with T2DM.
Keywords: Drug therapy, exenatide, GLP-1 receptor agonists, glycemic control, incretins, obesity, type 2 diabetes mellitus
Current Drug Therapy
Title: Incretin-Based Therapies in Patients with Type 2 Diabetes
Volume: 5 Issue: 2
Author(s): Jeffrey S. Freeman, DO
Affiliation:
Keywords: Drug therapy, exenatide, GLP-1 receptor agonists, glycemic control, incretins, obesity, type 2 diabetes mellitus
Abstract: Type 2 diabetes mellitus (T2DM) is a highly prevalent and progressive metabolic disease associated with significant morbidity and mortality. While glycemic control remains the cornerstone of disease treatment, successful T2DM management requires consideration of several comorbid risk factors including overweight/obesity, dyslipidemia, and hypertension. Early and aggressive treatment of patients with T2DM should be implemented to slow disease progression and prevent long-term complications. This necessitates the selection of antidiabetes agents that effectively lower hyperglycemia and target the other fundamental defects of T2DM. Treatment regimens should be individualized according to patient profiles and risk factors. This is especially germane for overweight/obese patients with T2DM, who have an even higher risk for complications. Several newer antidiabetes agents, in particular, incretin-based therapies, target the underlying defects of T2DM, provide glycemic control with beneficial effects on cardiovascular risk factors including lipids and blood pressure while avoiding weight gain. These represent important therapeutic options for the management of patients with T2DM.
Export Options
About this article
Cite this article as:
S. Freeman, DO Jeffrey, Incretin-Based Therapies in Patients with Type 2 Diabetes, Current Drug Therapy 2010; 5 (2) . https://dx.doi.org/10.2174/157488510791065094
DOI https://dx.doi.org/10.2174/157488510791065094 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Propranolol Safety Profile in Children
Current Drug Safety Autophagy Inhibition Rescues Against Leptin-Induced Cardiac Contractile Dysfunction
Current Pharmaceutical Design Effect of Inhibitors of Nitric Oxide in Animal Models and Future Directions for Therapy in Inflammatory Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Pharmacology and Literature Review Based on Related Death and Non-Fatal Case Reports of the Benzofurans and Benzodifurans Designer Drugs
Current Pharmaceutical Design Downregulation of Hepatic Carbonyl Reductase Type 1 in End-Stage Renal Disease
Drug Metabolism Letters Editorial [Hot Topic:Are the Pleiotropic Effects of Drugs Used for the Prevention of Cardiovascular Disease Clinically Relevant?(Executive Editors: M. Elisaf and E.N. Liberopoulos)]
Current Pharmaceutical Design The Effects of Obesity-Related Peptides on the Vasculature
Current Vascular Pharmacology Antiproliferative Efficacy of Angiotensin II Receptor Blockers in Prostate Cancer
Current Cancer Drug Targets Gonadal Hormones in Adolescent Females with β-Thalassemia in Relation to Iron Load
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Therapeutic Strategies Targeting Vascular Redox in Human Atherosclerosis
Recent Patents on Cardiovascular Drug Discovery The Use of Biomarkers for Assessing HAART-Associated Renal Toxicity in HIV-Infected Patients
Current HIV Research Age-related Changes in Pharmacodynamics: Focus on Drugs Acting on Central Nervous and Cardiovascular Systems
Current Drug Metabolism Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study
Current Pharmaceutical Design The Cardiovascular Effects of Metformin: Further Reasons to Consider An Old Drug as a Cornerstone in the Therapy of Type 2 Diabetes Mellitus
Current Vascular Pharmacology Investigation of Gene Expression Pattern of 5HTR2a and MAO-A in PBMCs of Individuals Who Had Been Exposed to Air Pollution in Highly Polluted Area
Recent Patents on Inflammation & Allergy Drug Discovery Anti-IL-1 β Therapies
Recent Patents on DNA & Gene Sequences Diagnosis of Surgically-Treatable Forms of Primary Aldosteronism
Current Hypertension Reviews Meet Our Editorial Board Member
Letters in Drug Design & Discovery Stroke and Hypertension: An Appraisal from Pathophysiology to Clinical Practice
Current Vascular Pharmacology Physical and Mental Functions of Cardiovascular Diseased Patients Decrease During the State of Emergency Initiated by the COVID-19 Pandemic in Japan
Reviews on Recent Clinical Trials